BINP — Bionoid Pharma Share Price
Last trade - 00:00- $67.06m
- $67.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 15.25 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2007 | 2008 | 2009 | 2010 | 2011 | 2012E | 2013E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bionoid Pharma Inc., formerly Bronya International Corp., is a medical device company. The Company develops and markets medical devices and technologies for the orthopedic and pain management markets. The Company develops and commercializes a platform called muscle pattern recognition (MPR), a clinical tool for the analysis of muscle function in patients presenting with back pain. MPR provides information regarding muscle recruitment patterns in patients suffering from neck and back pain that can assist healthcare professionals in the evaluation and treatment of neck and back injuries and illnesses. The Company, through BIOflex Medical Magnetics, Inc., develops and sells magnetic therapy devices. The Company sells its products through several channels, including Web-based sales; corporate partnerships; direct response television (DRTV); retail distribution; Internet catalogs, and through a network of distributors across the world.
Directors
- Warren Baker CHM (59)
- Robert Gradus CFO (47)
- Kenneth Aebi DRC
- Gail Gannon DRC
- Craig Lunsman DRC (64)
- Karin Monster DRC (32)
- Mark Tauscher DRC (66)
- Last Annual
- December 31st, 2011
- Last Interim
- September 30th, 2012
- Incorporated
- June 27th, 2006
- Public Since
- February 4th, 1998
- No. of Shareholders
- 290
- No. of Employees
- 13
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 56,830,968
- Address
- 17011 Beach Blvd Ste 900, HUNTINGTON BEACH, 92647
- Web
- Phone
- +1 7148412670
- Auditors
- Farber Hass Hurley LLP
Upcoming Events for BINP
Similar to BINP
20/20 Genesystems
Pink Sheets on Nasdaq
Aamaxan Transport
Pink Sheets on Nasdaq
Accustem Sciences
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 18:03 UTC, shares in Bionoid Pharma are trading at $1.18. This share price information is delayed by 15 minutes.
Shares in Bionoid Pharma last closed at $1.18 and the price had moved by -45.12% over the past 365 days. In terms of relative price strength the Bionoid Pharma share price has underperformed the S&P500 Index by -37.32% over the past year.
There is no consensus recommendation for this security.
Bionoid Pharma does not currently pay a dividend.
Bionoid Pharma does not currently pay a dividend.
Bionoid Pharma does not currently pay a dividend.
To buy shares in Bionoid Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.18, shares in Bionoid Pharma had a market capitalisation of $67.06m.
Here are the trading details for Bionoid Pharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BINP
Based on an overall assessment of its quality, value and momentum Bionoid Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionoid Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +21.55%.
As of the last closing price of $1.18, shares in Bionoid Pharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bionoid Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bionoid Pharma's management team is headed by:
- Warren Baker - CHM
- Robert Gradus - CFO
- Kenneth Aebi - DRC
- Gail Gannon - DRC
- Craig Lunsman - DRC
- Karin Monster - DRC
- Mark Tauscher - DRC